Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
US Open: Wall Street Pushes Back Expectations of Another Fed Hike
Marvell: Memory-market problems and opportunities
US trade deficit larger than expected 🗽 US indices hit all-time high
Morning Wrap: Stock Indices Rise as Bonds Extend Their Losing Streak (06.10.2026)